Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Carlos L Aviña-Cervantes"'
Autor:
Elizabeth Ruiz-Sánchez, Janet Jiménez-Genchi, Yessica M. Alcántara-Flores, Carlos J. Castañeda-González, Carlos L. Aviña-Cervantes, Petra Yescas, María del Socorro González-Valadez, Nancy Martínez-Rodríguez, Antonio Ríos-Ortiz, Martha González-González, María E. López-Navarro, Patricia Rojas
Publikováno v:
BMC Psychiatry, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background Cognitive functions represent useful endophenotypes to identify the association between genetic variants and schizophrenia. In this sense, the NR4A2 gene has been implicated in schizophrenia and cognition in different animal model
Externí odkaz:
https://doaj.org/article/1114cc9207a44e3fad93c8798f515ccb
Autor:
Yerye G. Mayén-Lobo, Mireya Alcaraz-Zubeldia, David J. Dávila-Ortiz de Montellano, Blanca A. Motilla-Frías, Mayumi Y. García-Manteca, Alberto Ortega-Vázquez, Carlos L. Aviña-Cervantes, Edgar D. Crail-Meléndez, Camilo Ríos, Marisol López-López, Nancy Monroy-Jaramillo
Publikováno v:
Brazilian Journal of Psychiatry.
Patients with psychotic disorders (PD) exhibit divergent outcomes in their clinical trajectories, which in part may result from glutathione (GSH)-related high-risk genotypes affecting their clinical course. We aimed to determine clozapine pharmacokin
Autor:
Ingrid Fricke-Galindo, Blanca E. Pérez-Aldana, Luis R. Macías-Kauffer, Susana González-Arredondo, David Dávila-Ortiz de Montellano, Carlos L. Aviña-Cervantes, Marisol López-López, Yaneth Rodríguez-Agudelo, Nancy Monroy-Jaramillo
Publikováno v:
Archives of medical research. 53(4)
Cognitive impairment in schizophrenia (SCZ) is a core feature, relevant for the disease prognosis and functional capacity of the patients. It has also been identified as an endophenotype and proposed as a genetic mechanism of risk for schizophrenia.W
Autor:
Marisol López-López, Nancy Monroy-Jaramillo, Carlos L Aviña-Cervantes, David José Dávila-Ortiz de Montellano, Camilo Ríos, Alberto Ortega-Vázquez, Luis Tristán-López, Yerye Gibrán Mayén-Lobo
Publikováno v:
Drug development researchREFERENCES. 82(5)
Clozapine (CLZ) is an atypical antipsychotic and the gold standard for refractory psychosis treatment. However, there is little information regarding pharmacogenetics of CLZ in patients with refractory psychosis and its clinical correlation with alco
Autor:
Petra Yescas, Patricia Rojas, Antonio Ríos-Ortiz, Nancy Martínez-Rodríguez, Yessica M Alcántara-Flores, María E López-Navarro, Janet Jiménez-Genchi, Carlos L Aviña-Cervantes, Elizabeth Ruiz-Sánchez, Carlos Castañeda-González, María Del Socorro González-Valadez, Martha González-González
Publikováno v:
BMC Psychiatry, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Psychiatry
BMC Psychiatry
Background Cognitive functions represent useful endophenotypes to identify the association between genetic variants and schizophrenia. In this sense, the NR4A2 gene has been implicated in schizophrenia and cognition in different animal models and cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51e71fffce5533bd6d3b56f9010af35a
https://doi.org/10.21203/rs.3.rs-53517/v1
https://doi.org/10.21203/rs.3.rs-53517/v1
Autor:
Jesús Ramírez-Bermúdez, Sergio Montes, Camilo Ríos, Carlos L Aviña-Cervantes, Araceli Diaz-Ruiz, Luis Tristán-López, Mayela Vaquero-Baez, Carlos Torner
Publikováno v:
BMC Psychiatry
BMC Psychiatry, Vol 19, Iss 1, Pp 1-7 (2019)
BMC Psychiatry, Vol 19, Iss 1, Pp 1-7 (2019)
Purpose The aim of present study is to measure plasma clozapine (CLZ) and N-desmethyl clozapine (DMC) as biomarkers to correlate drug concentrations with the appearance of preclinical adverse hematic effects. Methods A high-performance liquid chromat
Publikováno v:
Acta Neuropsychiatrica. 22:164-165
Autor:
Ortega‐Vázquez, Alberto, Mayen‐Lobo, Yerye G., Dávila‐Ortiz de Montellano, David J., Tristán‐López, Luis, Aviña‐Cervantes, Carlos L., Ríos, Camilo, López‐López, Marisol, Monroy‐Jaramillo, Nancy
Publikováno v:
Drug Development Research; Aug2021, Vol. 82 Issue 5, p685-694, 10p
Autor:
Mayén-Lobo, Yerye Gibrán1,2 (AUTHOR) djdodem@gmail.com, Martínez-Magaña, José Jaime3 (AUTHOR) jimy.10.06@gmail.com, Pérez-Aldana, Blanca Estela1 (AUTHOR) blankita0807@gmail.com, Ortega-Vázquez, Alberto1 (AUTHOR) betoov@yahoo.com.mx, Genis-Mendoza, Alma Delia3 (AUTHOR) adgenis@inmegen.gob.mx, Dávila-Ortiz de Montellano, David José2 (AUTHOR), Soto-Reyes, Ernesto4 (AUTHOR) esotoreyes@cua.uam.mx, Nicolini, Humberto3,5 (AUTHOR) hnicolini@inmegen.gob.mx, López-López, Marisol1 (AUTHOR) mlopez@correo.xoc.uam.mx, Monroy-Jaramillo, Nancy2 (AUTHOR) nancy97@unam.mx, Squassina, Alessio (AUTHOR)
Publikováno v:
Pharmaceuticals (14248247). Feb2021, Vol. 14 Issue 2, p118. 1p.